Pharmacokinetics of Chemotherapy Delivered by Ophthalmic Artery Chemosurgery

Part of the Essentials in Ophthalmology book series (ESSENTIALS)


Super-selective ophthalmic artery infusion of chemotherapy is a powerful treatment option for intraocular retinoblastoma. However, the dose and schedule for drug administration are selected empirically. Knowledge of the amount of chemotherapy that effectively targets the ocular structures after local delivery and the availability in the bloodstream that correlates with toxicity may provide guidance towards a more scientific approach. The pharmacokinetics of a chemotherapy agent after local delivery is an important concept that has many clinical implications and varies according to drug type and method of delivery. Pharmacokinetic studies have been carried out in different animal models and patients with retinoblastoma. In the present chapter we will discuss general concepts of pharmacokinetics and specifically, we will overview the current knowledge about topotecan and melphalan pharmacokinetics after super-selective ophthalmic artery infusion and the relationship with pharmacodynamic parameters in animals and patients. Differences, advantages and disadvantages of each model will be discussed for a better understanding.


Pharmacokinetics Topotecan Melphalan Swine model Retinoblastoma 


Financial Support: This work was supported by Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET, PIP Nr 11220090100343); Hospital JP Garrahan, Buenos Aires, Argentina; Agencia Nacional de Promoción Científica (PICT 2010-2271); Fund for Ophthalmic Knowledge (GLC, ACF), New York, NY, USA.

Compliance with Ethical Requirements: Dr. Schaiquevich and Dr. Chantada declare that they have no conflict of interest.

The present study followed the tenets of the Declaration of Helsinki and institutional review board approval was obtained. Written informed consent was obtained from the parent/guardian for being included in the study.

All experiments adhered the tenets of Hospital Garrahan Institutional Committee for Animal Care and the ARVO Statement for the use of animals in ophthalmic and vision research. Also, all institutional and national guidelines for the care and use of laboratory animals were followed.


  1. Abramson DH. Periocular chemotherapy for retinoblastoma: success with problems? Arch Ophthalmol. 2005;123:128–9.CrossRefPubMedGoogle Scholar
  2. Abramson DH. Retinoblastoma: saving life with vision. Annu Rev Med. 2014;65:171–84.CrossRefPubMedGoogle Scholar
  3. Abramson DH, Dunkel IJ, Brodie SE, et al. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115:1398–404.CrossRefPubMedGoogle Scholar
  4. Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP. Bilateral superselective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem therapy. Arch Ophthalmol. 2010;128:370–2.CrossRefPubMedGoogle Scholar
  5. Abramson DH, Marr BP, Dunkel IJ, et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/ or subretinal seeding: 2-year results. Br J Ophthalmol. 2012;96:499–502.CrossRefPubMedGoogle Scholar
  6. Athale UH, Stewart C, Kuttesch JF, et al. Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J Clin Oncol. 2002;20:88–95.CrossRefPubMedGoogle Scholar
  7. Carcaboso AM, Bramuglia GF, Chantada GL, et al. Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy. Invest Ophthalmol Vis Sci. 2007;48:3761–7.CrossRefPubMedGoogle Scholar
  8. Chantada GL, Fandino AC, Casak SJ, et al. Activity of topotecan in retinoblastoma. Ophthalmic Genet. 2004;25:37–43.CrossRefPubMedGoogle Scholar
  9. Chantada GL, Fandino AC, Carcaboso AM, et al. A phase I study of periocular topotecan in children with intraocular retinoblastoma. Invest Ophthalmol Vis Sci. 2009;50:1492–6.CrossRefPubMedGoogle Scholar
  10. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–6.CrossRefPubMedGoogle Scholar
  11. Cunha-Vaz JG. The blood retinal barriers system. Basic concepts and clinical evaluation. Exp Eye Res. 2004;78:715–21.CrossRefPubMedGoogle Scholar
  12. Dondelinger RF, Ghysels MP, Brisbois D, et al. Relevant radiological anatomy of the pig as a training model in interventional radiology. Eur Radiol. 1998;8:1254–73.CrossRefPubMedGoogle Scholar
  13. Dyer MA, Rodriguez-Galindo C, Wilson MW. Use of preclinical models to improve treatment of retinoblastoma. PLoS Med. 2005;2:e332.CrossRefPubMedCentralPubMedGoogle Scholar
  14. Francis JH, Gobin YP, Dunkel IJ, et al. Carboplatin +/- topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma. PLoS One. 2013;8:e72441.CrossRefPubMedCentralPubMedGoogle Scholar
  15. Francis JH, Schaiquevich P, Buitrago E, et al. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study. Ophthalmology. 2014;121:1810–7.CrossRefPubMedGoogle Scholar
  16. Gaudana R, Jwala J, Boddu SH, et al. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26:1197–216.CrossRefPubMedCentralPubMedGoogle Scholar
  17. Gobin YP, Dunkel IJ, Marr BP, et al. Combined, sequential intravenous and intra-arterial chemotherapy (bridge chemotherapy) for young infants with retinoblastoma. PLoS One. 2012;7:e44322.CrossRefPubMedCentralPubMedGoogle Scholar
  18. Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology. 2007;114:1378–83.CrossRefPubMedGoogle Scholar
  19. Hartmann O, Oberlin O, Lemerle J, et al. Acute leukemia in two patients treated with high-dose melphalan and autologous marrow transplantation for malignant solid tumors. J Clin Oncol. 1984;2:1424–5.PubMedGoogle Scholar
  20. Herben VMM, ten Bokkel HW, Beihnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet. 1996;31:85–102.CrossRefPubMedGoogle Scholar
  21. Hobbie WL, Ginsberg JP, Ogle SK, Carlson CA, Meadows AT. Fertility in males treated for Hodgkins disease with COPP/ABV hybrid. Pediatr Blood Cancer. 2005;44:193–6.CrossRefPubMedGoogle Scholar
  22. Hocht C, Opezzo JA, Taira CA. Microdialysis in drug discovery. Curr Drug Discov Technol. 2004;1:269–85.CrossRefPubMedGoogle Scholar
  23. Hosoya K, Kyoko H, Toyooka N, et al. Evaluation of amino acid mustard transport as L-type amino acid transporter 1 (LAT1)-mediated alkylating agents. Biol Pharm Bull. 2008;31:2126–30.CrossRefPubMedGoogle Scholar
  24. Inomata M, Kaneko A. Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay. Jpn J Cancer Res. 1987;78:858–68.PubMedGoogle Scholar
  25. Kaneko A, Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol. 2003;33:601–7.CrossRefPubMedGoogle Scholar
  26. Klaase JM, Kroon BB, Beijnen JH, et al. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer. 1994;70:151–3.CrossRefPubMedCentralPubMedGoogle Scholar
  27. Laurie NA, Gray JK, Zhang J, et al. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res. 2005;11:7569–78.CrossRefPubMedGoogle Scholar
  28. Marr BP, Brodie SE, Dunkel IJ, Gobin YP, Abramson DH. Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results. Br J Ophthalmol. 2012;96:1300–3.CrossRefPubMedGoogle Scholar
  29. Moren H, Undren P, Gesslein B, et al. The porcine retinal vasculature accessed using an endovascular approach: a new experimental model for retinal ischemia. Invest Ophthalmol Vis Sci. 2009;50:5504–10.CrossRefPubMedGoogle Scholar
  30. Munier FL, Gaillard MC, Balmer A, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. 2012;96:1078–83.CrossRefPubMedGoogle Scholar
  31. Nath CE, Shaw PJ, Montgomery K, Earl JW. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients. Br J Clin Pharmacol. 2007;64:151–64.CrossRefPubMedCentralPubMedGoogle Scholar
  32. Nemeth KM, Federico S, Carcaboso AM, et al. Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma. Cancer. 2011;117:421–34.CrossRefPubMedCentralPubMedGoogle Scholar
  33. Palioura S, Gobin YP, Brodie SE, et al. Ophthalmic artery chemosurgery for the management of retinoblastoma in eyes with extensive (>50%) retinal detachment. Pediatr Blood Cancer. 2012;59:859–64.CrossRefPubMedGoogle Scholar
  34. Panetta JC, Schaiquevich P, Santana VM, et al. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma. Clin Cancer Res. 2008;14:318–25.CrossRefPubMedGoogle Scholar
  35. Pritchard J, Cotterill SJ, Germond SM, et al. Jones DR. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer. 2005;44:348–57.CrossRefPubMedGoogle Scholar
  36. Qaddoumi I, Billups CA, Tagen M, et al. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer. 2012;118:5663–70.CrossRefPubMedCentralPubMedGoogle Scholar
  37. Ritschel WA, Kearns GL, editors. Handbook of basic pharmacokinetics including clinical applications. American Pharmacist Association: Washington, DC; 2004.Google Scholar
  38. Santana VM, Zamboni WC, Kirstein MN, et al. A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin Cancer Res. 2003;9:633–40.PubMedGoogle Scholar
  39. Saylors 3rd RL, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19:3463–9.PubMedGoogle Scholar
  40. Schaiquevich P, Buitrago E, Ceciliano A, et al. Pharmacokinetic analysis of topotecan after superselective ophthalmic artery infusion and periocular administration in a porcine model. Retina. 2012a;32:387–95.CrossRefPubMedGoogle Scholar
  41. Schaiquevich P, Buitrago E, Taich P, et al. Pharmacokinetic analysis of melphalan after super-selective ophthalmic artery infusion in preclinical models and retinoblastoma patients. Invest Ophthalmol Vis Sci. 2012b;53:4205–12.CrossRefPubMedGoogle Scholar
  42. Schaiquevich P, Ceciliano A, Millan N, et al. Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatr Blood Cancer. 2013;60:766–70.CrossRefPubMedGoogle Scholar
  43. Schaiquevich P, Carcaboso AM, Buitrago E, et al. Ocular pharmacology of topotecan and its activity in retinoblastoma. Retina. 2014;34:1719–27.CrossRefPubMedGoogle Scholar
  44. Schrijvers D, Pronk L, Highley M, et al. Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study. Am J Clin Oncol. 2000;23:358–63.CrossRefPubMedGoogle Scholar
  45. Taich P, Ceciliano A, Buitrago E, et al. Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma. Ophthalmology. 2014;121:889–97.CrossRefPubMedGoogle Scholar
  46. Tse BC, Steinle JJ, Johnson D, Haik BG, Wilson MW. Super selective intraophthalmic artery chemotherapy in a nonhuman primate model: histopathologic findings. JAMA Ophthalmol. 2013;131:903–11.CrossRefPubMedCentralPubMedGoogle Scholar
  47. Tubergen DG, Stewart CF, Pratt CB, et al. Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a Pediatric Oncology Group Study. J Pediatr Hematol Oncol. 1996;18:352–61.CrossRefPubMedGoogle Scholar
  48. Wahlin A, Roos G, Rudolphi O, Holm J. Melphalan-related leukemia in multiple myeloma. Acta Med Scand. 1982;211:203–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Clinical Pharmacokinetics UnitHospital de Pediatría JP GarrahanBuenos AiresArgentina
  2. 2.CONICETBuenos AiresArgentina
  3. 3.Service of Hemato-OncologyHospital de Pediatría JP GarrahanBuenos AiresArgentina

Personalised recommendations